RxDoctor Payments DataLook up a doctor →

Robert Tassan, MD

Hematology · Westwood, NJNPI 1578596508

Payments from drug & device makers

$21,198in general payments, 2019–2025

Across 1,386 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Daiichi Sankyo Inc.$1K
  • AstraZeneca$1K
  • Merck$1K
  • Bristol Myers Squibb$1K
  • Rigel Pharmaceuticals, Inc.$971
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$20,99999%
  • Education$1981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis173$2,723
Daiichi Sankyo Inc.127$1,292
AstraZeneca(2 entities)76$1,216
Merck80$1,175
Bristol Myers Squibb81$1,135
Rigel Pharmaceuticals, Inc.57$971
Incyte Corporation47$743
E.r. Squibb & Sons, L.L.C.54$733
Amgen44$731
Johnson & Johnson(2 entities)37$694
AbbVie41$655
Pfizer43$643
Astellas Pharma US Inc38$573
Pharmacyclics LLC, An Abbvie Company32$481
Karyopharm Therapeutics Inc.30$440
Taiho Oncology, Inc.25$416
Genentech USA, Inc.22$382
Bayer23$379
Seagen Inc.22$349
Sanofi19$319
Pharmaessentia USA Corporation18$272
Eisai Inc.17$254
GSK13$216
Agios Pharmaceuticals, Inc.11$199
Puma Biotechnology, Inc.15$199
Mirati Therapeutics, Inc.11$192
Boehringer Ingelheim13$178
Blueprint Medicines Corporation9$163
Coherus Oncology, Inc.10$144
Array Biopharma Inc10$143
Exelixis Inc.8$143
Jazz Pharmaceuticals Inc.8$140
Lilly USA, LLC10$137
Sobi, Inc9$135
Regeneron Healthcare Solutions, Inc.8$132
Takeda Pharmaceuticals U.S.A., Inc.6$120
Foundation Medicine, Inc.4$112
Aurobindo Pharma USA, Inc.7$109
Stemline Therapeutics Inc.5$86
AVEO Pharmaceuticals, Inc.4$86
AMAG Pharmaceuticals, Inc.6$86
Tersera Therapeutics LLC5$84
Pharmacosmos Therapeutics Inc.5$83
Emmaus Medical, Inc.4$77
Apellis Pharmaceuticals, Inc.4$76
Gilead(2 entities)4$75
Kyowa Kirin, Inc.5$74
Dendreon Pharmaceuticals LLC4$73
Epizyme, Inc.5$72
Beigene USA, Inc.4$72
Recordati_rare_diseases_inc.4$70
Ipsen Biopharmaceuticals, Inc4$63
Adaptive Biotechnologies Corporation3$61
Alnylam Pharmaceuticals Inc.4$58
EMD Serono, Inc.4$58
G1 Therapeutics, Inc.3$50
Servier Pharmaceuticals LLC3$45
Acceleron Pharma, Inc.3$44
ADC Therapeutics America, Inc.2$41
Shorla Oncology Inc.2$38

How this compares

$21,198 in reported general payments places this provider in the 75th percentile of 43 hematology providers in New Jersey.

See all hematology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,229,342
Medicare patients
878
Services billed
57,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GivlaariGivosiran Sodium13$1,033,680
ImbruvicaIbrutinib57$884,761
PromactaEltrombopag Olamine20$355,717
IbrancePalbociclib13$206,343
JakafiRuxolitinib Phosphate13$199,258
EliquisApixaban178$187,361
XareltoRivaroxaban54$73,913
Deferasirox37$4,146
Hydroxyurea123$3,539
Anastrozole27$845
Azathioprine14$243
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen25$236
Gabapentin14$225
Warfarin Sodium19$213
Oxycodone Hcl22$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alnylam Pharmaceuticals Inc.Givlaari$58$1,033,68013 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$481$884,76157 claims
PfizerIbrance, Eliquis$643$393,704191 claims
NovartisPromacta$2,723$355,71720 claims
Incyte CorporationJakafi$743$199,25813 claims
Johnson & JohnsonXarelto$694$73,91354 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 43 hematology providers in New Jersey.

Other hematology in Westwood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →